Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics reports developments as a clinical-stage biotechnology company developing immunology therapies for autoimmune and chronic inflammatory diseases. Company news centers on rezpegaldesleukin, also known as REZPEG or NKTR-358, a regulatory T cell stimulator evaluated across disease areas including atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.
Recurring updates also cover Nektar's preclinical pipeline, including TNFR2 antibody and bispecific programs NKTR-0165 and NKTR-0166, and the modified hematopoietic colony stimulating factor protein NKTR-422. Financial results, public equity offerings, shelf-registration activity, employee inducement grants, and other capital and governance actions are regular news themes for NKTR.
Nektar Therapeutics (NASDAQ:NKTR) reported inducement grants made on May 20, 2026 under its 2025 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The Board’s committee granted non-qualified options for 11,900 shares to five new employees at a $69.49 exercise price, with eight-year terms and four-year vesting.
Nektar Therapeutics (Nasdaq: NKTR) will participate in the 2026 Jefferies Global Healthcare Conference in New York. Management’s fireside chat is scheduled for Wednesday, June 3, 2026 at 1:20 p.m. ET and will be webcast live.
The webcast and 30-day replay will be accessible via Nektar’s investor events webpage.
Nektar Therapeutics (Nasdaq: NKTR) reported Q1 2026 results for the quarter ended March 31, 2026. Cash and marketable securities were $731.6 million at March 31, 2026, excluding approximately $351 million net proceeds from a secondary offering closed April 23, 2026. Revenue was $10.9 million. Total operating costs were $49.9 million; R&D expense was $35.7 million. Net loss was $44.9 million or $1.82 per share. Recent financings in February and April generated gross proceeds of $460 million and $373.8 million, respectively. Key upcoming milestones include Phase 3 ZENITH-AD initiation by July 2026 and an FDA End-of-Phase 2 meeting for alopecia areata in Q2 2026.
Nektar Therapeutics (NASDAQ:NKTR) announced inducement equity grants on April 20, 2026 under its 2025 Inducement Plan. The Organization and Compensation Committee granted non-qualified stock options for 28,450 shares and 2,950 RSUs to six newly hired employees.
Options have an $100.35 exercise price, eight-year term, and standard four-year vesting; RSUs vest over four years with quarterly vesting after year one.
Nektar Therapeutics (Nasdaq: NKTR) will report first-quarter 2026 financial results on Thursday, May 7, 2026, after the U.S. market close. Howard Robin, president and CEO, will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT to review results.
The live audio-only webcast and press release will be available via the company’s investor website. The web broadcast replay will remain available through June 7, 2026. Registrants will receive dial-in details and a PIN; pre-registration is required for call access.
Nektar Therapeutics (Nasdaq: NKTR) closed an underwritten public offering on April 23, 2026, raising approximately $373.8 million in gross proceeds.
The company sold 4,062,500 shares at $92.00 per share, including 529,891 shares issued upon full exercise of the underwriters' option. Joint bookrunners were Jefferies, TD Cowen, and Piper Sandler; Citigroup acted as bookrunner. The offering was made under a Form S-3ASR shelf registration effective November 12, 2025, and final prospectus materials are available via the SEC and the bookrunners listed.
Nektar Therapeutics (Nasdaq: NKTR) priced an upsized underwritten public offering of $325 million by selling 3,532,609 shares at $92.00 per share, with a 30‑day option to purchase up to 529,891 additional shares. The offering is expected to close on April 23, 2026.
Net proceeds are intended for general corporate purposes including research and development, clinical development (notably Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing costs. Jefferies, TD Cowen, Piper Sandler, and Citigroup are acting as bookrunners. The offering is made on a Form S-3ASR registration.
Nektar Therapeutics (Nasdaq: NKTR) has commenced a proposed underwritten public offering of $250,000,000 of common stock and, in lieu of common shares for certain investors, pre-funded warrants. Nektar may grant underwriters a 30-day option to purchase up to an additional $37,500,000 of common stock.
Proceeds are intended for general corporate purposes, including R&D and Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata. The offering is subject to market conditions and may not be completed as proposed.
Nektar Therapeutics (Nasdaq: NKTR) reported 52-week topline results from a 16-week blinded extension of the Phase 2b REZOLVE-AA study of rezpegaldesleukin in severe-to-very-severe alopecia areata. Continued twice-monthly dosing increased responder rates (SALT≤20, SALT30, SALT50) with a favorable safety profile and 94% completion.
Low-dose and high-dose arms reached 25.8% and 27.6% SALT≤20 at week 52 versus 6.7% placebo (p=0.049); safety remained mostly mild-to-moderate TEAEs.
Nektar (Nasdaq: NKTR) will host an investor call and live webcast on April 20, 2026 at 8:00 am ET / 5:00 am PT to review 52-week topline results from the 16-week extension treatment period of the Phase 2b REZOLVE-AA study of rezpegaldesleukin for severe-to-very-severe alopecia areata.
The company will issue a morning press release, present slides during the webcast, and post the materials and a replay on its investor events page for at least 30 days.